Biotechnology US pharma giant Merck, known as MSD outside the USA and Canada, yesterday announced that Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, received new approvals from the Japan Pharmaceuticals and Medical Devices Agency (PMDA) in advanced renal cell carcinoma (RCC) and head and neck cancer for the following additional indications in Japan: 21 December 2019